Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sea Change In China’s Anti-Cancer Market Shares

This article was originally published in PharmAsia News

Executive Summary

China's hospitals are increasingly turning to alkaloid products such as paclitaxel and docetaxel to treat cancer while immunostimulant anti-cancer products see a decline in use, despite owning the largest market share

You may also be interested in...

Sanofi-Aventis Set To Appeal Invalidation Of Drug Patent In China

BEIJING - In the latest twist in one of the most closely followed pharmaceutical patent disputes ever in China, an executive at Sanofi-Aventis said the company will appeal the recent invalidation of its patent for an injectable anti-cancer drug in Beijing

Sanofi-Aventis To Work With Chinese Experts In Cancer Stem-Cell Research

SHANGHAI - Sanofi-Aventis will expand its footprint in China by collaborating with Tianjin's Institute of Hematology and Blood Diseases Hospital (IHBDH) in the field of cancer stem cells, the French drug maker announced Sept. 14

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts